

Supporting Information

Metabolic flexibility maintains proliferation and migration of FGFR signaling-deficient lymphatic endothelial cells

Hongyuan Song^{1*}, Jie Zhu^{1*}, Ping Li¹, Fei Han¹, Longhou Fang^{2,3,4}, and Pengchun Yu^{1,5}

¹Cardiovascular Biology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK 73104, USA.

²Center for Cardiovascular Regeneration, Department of Cardiovascular Sciences, Houston Methodist Research Institute, Houston, TX 77030, USA.

³Department of Ophthalmology, Blanton Eye Institute, Houston Methodist Institute for Academic Medicine, Houston Methodist Research Institute, Houston, TX 77030, USA.

⁴Department of Cardiothoracic Surgeries, Weill Cornell Medical College, Cornell University, New York City, NY 10065, USA.

⁵Department of Cell Biology, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA.

* Contributed equally

Correspondence:

Pengchun Yu

Cardiovascular Biology Research Program

Oklahoma Medical Research Foundation

825 NE 13th Street, Oklahoma City, OK 73104


Tel: 405-271-4445

Email: Pengchun-Yu@omrf.org

List of Supporting Information


1. Supplemental Figure 1
2. Supplemental Figure 2
3. Supplemental Figure 3

Supplemental Figure 1




Supplemental Figure 1: Confirmation of the effect of FGFR1 knockdown on HK2 and CPT1A expression using a second siRNA. (A) Western blot analysis of CPT1A, HK2, and FGFR1 proteins in HDLECs transfected with control siRNA or a second siRNA targeting FGFR1. α -Tubulin served as a loading control. (B, C) Densitometric quantification of HK2 proteins (n=3 independent experiments) (B) and CPT1A proteins (n=3 independent experiments) (C). Data represent mean \pm s.d.; p values were calculated by unpaired *t*-test.

Supplemental Figure 2



Supplemental Figure 2: Inhibition of glycolysis per se does not affect CPT1A expression. (A, B) Western blot analysis (A) and densitometric quantification (n=3 replicates from two independent experiments) (B) of CPT1A proteins in HDLECs treated with vehicle or 2DG. α -Tubulin served as a loading control. Data represent mean \pm s.d.; the p value was calculated by unpaired *t*-test.

Supplemental Figure 3



Supplemental Figure 3: Confirmation of the effect of FGFR1 or PPAR α knockdown using a second siRNA. (A) Western blot analysis of phosphorylated ERK1/2 (Thr202/Tyr204) and total ERK1/2 in HDLECs transfected with control siRNA or a second siRNA targeting FGFR1 (representative of three independent experiments). (B) qPCR analysis of *CPT1A* mRNA in HDLECs transfected with control siRNA or a second siRNA targeting FGFR1 (n= 3 technical replicates; representative of two independent experiments). (C) Western blot analysis of CPT1A expression in HDLECs transfected control siRNA, FGFR1 siRNA, or a combination of FGFR1 siRNA and a second siRNA targeting PPAR α . β -actin was examined as a loading control. The result is representative of two independent experiments. (D) qPCR analysis of *PPARA* mRNA in HDLECs transfected with control siRNA or a second siRNA targeting FGFR1 (n= 3 technical replicates; representative of two independent experiments). Data represent mean \pm s.d.; p values were calculated by unpaired *t*-test.